Key Points
- CEO Kristen Fortney sold 233,107 shares on Jan. 13 at an average price of $18.12 for about $4.22M, cutting her holding by 19.26% to 976,949 shares (SEC filing).
- BIOA shares fell 6.2%, opened at $21.51, and trade within a 12‑month range of $2.88–$24.00; the company has a market cap of $771.1M and a negative P/E of -14.15.
- Analyst views are mixed: Citigroup rates the stock a buy with a $15 target while other firms have downgraded to sell, leaving a MarketBeat consensus of "Hold" and an average target of $15.
BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) CFO Dov Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
BioAge Labs Stock Performance
BIOA stock opened at $21.51 on Friday. The firm has a 50 day simple moving average of $11.96 and a 200 day simple moving average of $7.53. BioAge Labs, Inc. has a 52 week low of $2.88 and a 52 week high of $24.00. The stock has a market cap of $771.13 million, a P/E ratio of -14.15 and a beta of 1.38.
BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.
Wall Street Analyst Weigh In
BIOA has been the topic of several research reports. Citigroup upped their target price on BioAge Labs from $10.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, October 29th. Weiss Ratings restated a "sell (d-)" rating on shares of BioAge Labs in a report on Thursday, October 30th. Finally, Wall Street Zen lowered shares of BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $15.00.
Get Our Latest Stock Report on BIOA
Institutional Investors Weigh In On BioAge Labs
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company's stock worth $1,873,000 after buying an additional 171,426 shares during the period. Millennium Management LLC boosted its holdings in shares of BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company's stock worth $1,803,000 after buying an additional 270,479 shares during the period. Marshall Wace LLP raised its holdings in BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company's stock worth $937,000 after acquiring an additional 173,388 shares during the period. Finally, Stonepine Capital Management LLC lifted its position in BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company's stock worth $624,000 after acquiring an additional 101,085 shares during the last quarter.
BioAge Labs Company Profile
(
Get Free Report)
BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.
At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
